David Schenkein

General Partner @GVteam
Hematologist/Medical Oncologist

[David Schenkein @schenkein]

Congrats to the entire Parabilis team- making an impact on the lives of patients in need

[GV @GVteam]

Congratulations to the entire team at Parabilis Medicines on going public today.
Since our first investment in 2018, it has been an honor to support Greg, @mmammen, and team as they translate complex science into clinical results.

[David Schenkein @schenkein]

Was an incredibly special time in my career and honored to be with such an amazing group of people dedicated to make an impact

[Vincent Rajkumar @VincentRK]

This author list! 👇

[David Schenkein @schenkein]

This prize is so well deserved and I am honored to be a colleague of Dr. Kathy High at Rhygaze

[Breakthrough @brkthroughprize]

Congratulations to Jean Bennett, Katherine A. High and Albert Maguire, winners of the 2026 Breakthrough Prize in Life Sciences, for developing a therapy for inherited retinal degeneration that became the first FDA-approved gene therapy for a genetic disease. https://t.co/awmRtAX5vT
@Penn @ChildrensPhila @RockefellerUniv

[David Schenkein @schenkein]

@jodiesjunction Thanks for reaching out- what was his name?

[David Schenkein @schenkein]

Great news for patients with SCD- great work by Sarah and the entire @AgiosPharma team- making an impact

[Agios @AgiosPharma]

#AgiosNews: We will pursue U.S. accelerated approval for our first-in-class oral pyruvate kinase (PK) activator in #SickleCellDisease, following completion of our pre-supplemental New Drug Application (sNDA) meeting with the @US_FDA. Read more: https://t.co/FLbZVm0ewd

[David Schenkein @schenkein]

Thanks for sharing @davidrliu : so proud of the team at @PrimeMedicine : making an impact with an extraordinary technology

[David R. Liu @davidrliu]

Below is the story of the first patient treated with a prime-edited therapeutic, developed by @PrimeMedicine in a trial led by Dr. Élie Haddad and his team at CHU Sainte-Justine. This teenager suffered from chronic granulomatous disease (CGD), an immunodeficiency, and now—10 months after treatment—the patient is healthy, stable, and living with a functioning immune system. Tracy Attebury, whose story was previously told by @ginakolata @nytimes, was the second patient treated with a prime-edited therapeutic.

https://t.co/ZiVq1SmYsn

[David Schenkein @schenkein]

Congratulations to the entire @AgiosPharma team- making yet another huge impact for patients in need. Go Agios!!!!

[Agios @AgiosPharma]

#AgiosNews: @US_FDA approved our first-in-class pyruvate kinase (PK) activator for the treatment of anemia in adults with alpha- or beta-thalassemia – regardless of transfusion status.

Read more here: https://t.co/sP9t49O2dX

[David Schenkein @schenkein]

Congratulations Rob- so well deserved

[Dana-Farber @DanaFarber]

Congratulations to Robert Soiffer, MD, the 2025 recipient of the Edward J. Benz Award for Advancing the Careers of Dana-Farber Faculty. This annual award recognizes a faculty member who goes above and beyond to advance the careers of fellow faculty. We thank Dr. Soiffer for his continued dedication and leadership, which truly exemplify this honor.

[David Schenkein @schenkein]

Congrats to the awesome teams @Servier and @AgiosPharma for the development of vorasidenib for patients with Glioma

[Servier Pharmaceuticals @ServierPharma]

We’re proud to share that Servier has been awarded the 2025 #PrixGalien USA Award in the Best Product for Rare/Orphan Diseases category!

Thank you to the @GalienFdn for this incredible honor. It’s a true privilege to have our work in advancing glioma care recognized.

[David Schenkein @schenkein]

Congratulations to the @PelagePharma team and the @GVteam is excited to welcome Arch Ventures into the syndicate

[GV @GVteam]

.@PelagePharma is combating hair loss by developing regenerative medicines that reactivate dormant stem cells to restart hair growth.

With its new Series B funding, Pelage will advance its PP405 program toward Phase 3 trials in 2026. Congrats to the team on this major milestone!

[David Schenkein @schenkein]

Congratulations to the entire @AgiosPharma team- excited for the patients who will benefit

[Agios @AgiosPharma]

#AgiosNews: @Saudi_fda_en approved our first-in-class pyruvate kinase (PK) activator for the treatment of adult patients with thalassemia. This marks the first regulatory approval for this medicine in thalassemia. Read more: https://t.co/QiH3ciyUmj

[David Schenkein @schenkein]

Congratulations to @skathire and the entire Verve team- will be exciting to see the programs continue to move forward for the patients at need

[Sek Kathiresan MD @skathire]

Today, we take the next step in Verve’s journey: the acquisition by @EliLillyandCo is now complete.

From the founding of Verve in 2018 to this milestone in 2025, we have worked with urgency and conviction to advance a bold idea — that a single-course gene editing medicine could one day offer durable protection from atherosclerotic cardiovascular disease.

Lilly shares our vision of changing the treatment paradigm for cardiovascular disease. We believe Verve + Lilly is a uniquely powerful combination — one that brings together complementary strengths to deliver on the promise of single-course gene editing medicines for millions around the world.

To the Verve team: thank you. Your drive, grit, and heart made this possible. And to the investigators and patients who have participated in our trials — we are deeply grateful.

https://t.co/8tcfqaE455

$VERV $LLY

[David Schenkein @schenkein]

@VincentRK @NEJM It was a remarkable collaboration between industry and academic scientists and physicians in the best interest of patients

[David Schenkein @schenkein]

David- congratulations on such a well deserved recognition for the tremendous impact these medicines will make on patients around the world

[David R. Liu @davidrliu]

Last night I was honored to receive the 2025 #BreakthroughPrize in the Life Sciences, reflecting the efforts of many students, collaborators, doctors, and patients in labs around the world. I hope this 4-minute excerpt can inspire when science needs public support more than ever.

[David Schenkein @schenkein]

I am so proud of the entire @AgiosPharma team on another important clinical milestone and proud of the impact we will have on children with this disease that currently has no treatment options other than supportive care.

[Agios @AgiosPharma]

#AgiosNews: Our ACTIVATE-Kids Phase 3 study of our late-stage pyruvate kinase (PK) activator in children aged 1 to <18 years with PK deficiency who are not regularly transfused achieved its primary endpoint. This is the first study to demonstrate efficacy of an oral therapy for children with #PKDeficiency who are not regularly transfused. With today’s news, the double-blind period of both of our pediatric PK deficiency trials – ACTIVATE-Kids and ACTIVATE-KidsT – has now been completed. Read more: https://t.co/IEimGeGsla

[David Schenkein @schenkein]

Congratulations to Sarah and the entire @AgiosPharma team

[Agios @AgiosPharma]

@US_FDA accepted our supplemental New Drug Application for our late-stage PK activator for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. The Prescription Drug User Fee Act (PDUFA) goal date is September 7, 2025. Read more: https://t.co/wa5Izleens

[David Schenkein @schenkein]

Congratulations to Sarah and the entire @AgiosPharma team for this great accomplishment

[Agios @AgiosPharma]

We completed enrollment of our Phase 3 RISE UP trial in #sicklecelldisease. The topline results from this 52-week study are expected in late 2025. Read more: https://t.co/DCoDKQLCaX

[David Schenkein @schenkein]

Exciting collaboration with ⁦@bmsnews⁩ to develop suite of new medicines- congratulations to ⁦@PrimeMedicine⁩ and ⁦@bmsnews⁩ https://t.co/bl8m79l9e1

[David Schenkein @schenkein]

Thrilled to be working with this amazing group of people and excited by the impact we are and will be making in some many important areas in digital and healthcare.

[David Krane @kraneland]

Happy 15th birthday, @gvteam! 🎂Thanks to @FortuneMagazine's @agarfinks for spending time with us, as we celebrate GV's history, and look toward the next 300 years... 🚀

[David Schenkein @schenkein]

Incredibly proud of both the @AgiosPharma and @ServierPharma teams- changing the landscape for patients with IDH glioma- great day for these patients

[Agios @AgiosPharma]

We're thrilled to share the FDA has approved vorasidenib, representing a significant step forward for patients. Congrats to @ServierPharma and the Agios team for their early discovery and development efforts. Read more: https://t.co/4IH1n2cAsZ